| Insurance Carrier | Facility/Professional | Modifier | Typical Low | Median | Typical High |
|---|
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection, and post administration monitoring in the home or residence. This includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses
| Insurance Carrier | Facility/Professional | Modifier | Typical Low | Median | Typical High |
|---|